Alpine Immune Sc: Securities to be offered to employees in employee benefit plans, post-effective amendments
Press release · 05/20 16:04
Weekly Report: what happened at ALPN last week (0513-0517)?
Weekly Report · 05/20 11:31
What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. The company is developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. 11 analysts have recently evaluated Alpine Immune sciences and provided 12-month price targets. The average price target is $ and the company's revenue growth has faced challenges.
Benzinga · 05/16 13:00
Alpine Immune Sciences Price Target Maintained With a $65.00/Share by Wedbush
Dow Jones · 05/16 12:48
Wedbush Reiterates Neutral on Alpine Immune Sciences, Maintains $65 Price Target
Benzinga · 05/16 12:38
Analysts Offer Insights on Healthcare Companies: Eyenovia (EYEN), Alpine Immune Sciences (ALPN) and GoodRx Holdings (GDRX)
TipRanks · 05/16 12:20
ALPN Factor-Based Stock Analysis
NASDAQ · 05/15 20:12
XBI, ALPN, RVMD, IBRX: Large Outflows Detected at ETF
NASDAQ · 05/15 16:14
Weekly Report: what happened at ALPN last week (0506-0510)?
Weekly Report · 05/13 11:45
Alpine Immune Sc: Statement of changes in beneficial ownership of securities
Press release · 05/11 00:07
Alpine Immune ticks higher as HSR waiting period for Vertex Pharma deal expires
Alpine Immune Sciences, Inc. Edged higher as HSR waiting period for its planned sale to Vertex Pharmaceuticals expired. Vertex agreed to acquire Alpine for $65 per share or about $4.9 billion in cash last month. Alpine Immune's stock rose 0.2% as the HSR period for Vertex Pharma deal expires.
Seeking Alpha · 05/10 16:44
Alpine Immune Sciences, Inc. Form 10-Q for the Quarter Ended March 31, 2024
Press release · 05/10 13:23
RBC Capital Sticks to Its Hold Rating for Alpine Immune Sciences (ALPN)
TipRanks · 05/10 10:39
ALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q1 2024
Alpine Immune Sciences reported earnings per share of -28 cents for the first quarter of 2024. The company reported revenue of $7.03 million. This was 99.77% better than the analyst estimate for the same period. Alpine Immune sciences is a biotechnology company.
Investorplace · 05/10 02:56
Alpine Immune Sciences GAAP EPS of -$0.28 beats by $0.12, revenue of $7.03M beats by $3.51M
Seeking Alpha · 05/09 21:50
Alpine Immune Sciences Inc reports results for the quarter ended in January - Earnings Summary
Alpine Immune Sciences Inc reports results for the quarter ended in January. The company reported a quarterly adjusted loss of 28 cents per share. Revenue fell 25.1% to $7.03 million from the same quarter last year. Shares had risen by 63.2% this quarter and 239.5% this year.
Reuters · 05/09 21:36
Alpine Immune Sciences Q1 EPS $(0.28) Beats $(0.41) Estimate, Sales $7.03M Beat $3.52M Estimate
Alpine Immune Sciences reported quarterly losses of $0.28 per share. The company also reported quarterly sales of $7.03 million. This is a 25.09 percent decrease over the same period last year. The firm beat the analyst consensus estimate of losses by 31.71 percent.
Benzinga · 05/09 20:25
Alpine Immune Sciences Communicates Key Updates Regularly
TipRanks · 05/09 20:24
*Alpine Immune Sciences Anticipates Cash and Investments Sufficient to Fund Planned Ops Into 2026 >ALPN
Dow Jones · 05/09 20:16
*Alpine Immune Sciences: Vertex Pharma Deal Anticipated to Close in 2Q
Dow Jones · 05/09 20:15
Webull provides a variety of real-time ALPN stock news. You can receive the latest news about Alpine Immune Sc through multiple platforms. This information may help you make smarter investment decisions.
About ALPN
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.